August 22, 2024 02:25 PM EDT

FDA closes the door on Intarcia's eight-year bid for diabetes drug-device combo

Zachary Brennan

Senior Editor

The FDA on Thursday issued an order denying Intarcia’s appeal over its rejected type 2 diabetes combo product, ending nearly eight years of back-and-forth on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA closes the door on Intarcia's eight-year bid for diabetes drug-device combo

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Moderna plans $1.1B in R&D and program cuts, delays break-even point to 2028

Sofinnova’s Jim Healy on ‘more rational market’ as four biotech startups near their IPOs

Charles River to lay off 3% of staffers as it streamlines spending

Fulcrum's Phase 3 for old GSK drug fails, stock sinks

Sanofi buys into radiopharmaceutical field with $110M upfront, going after space held by Novartis

A new startup wants to fight cancer with 'off-the-shelf' gene therapy, securing $26M seed round

FDA clos­es the door on Intar­ci­a's eight-year bid for di­a­betes drug-de­vice com­bo

Senior Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

FDA closes the door on Intarcia's eight-year bid for diabetes drug-device combo